Buying for the Long Haul? These 3 Stocks Could Generate 10x Returns
The article highlights three higher-risk growth stocks for long-term investors: Joby Aviation (JOBY), Curaleaf Holdings (CURLF), and Pony AI (PONY). It says Joby has a ~$12B market cap but lacks U.S. aircraft approval and posted a $930M loss last year. Curaleaf reported 2025 operating income of $25M on ~$1.3B revenue. Pony AI, with ~$5B market cap, reported Q1 revenue of $34.3M (+145% YoY) but an operating loss of $58.3M over the past three months.
How this was made
The 30-second read
Why it matters
The article is primarily thesis-based; it does not report a new company-specific corporate action (no earnings release, deal, or regulatory decision). It does provide a few concrete datapoints (Curaleaf operating income/revenue; Pony AI revenue growth and operating loss; Joby prior-year loss and approval status).
Market read
Useful for positioning in high-volatility growth themes, but lacks a fresh, time-stamped catalyst that would typically drive an immediate trading decision.
What to watch
For Joby and Pony AI, the key missing trading inputs are cash runway, funding plans, and concrete regulatory milestones; for Curaleaf, the article doesn’t quantify how rescheduling translates into revenue/market share or timing of legalization.
Background
This is a Motley Fool-style long-term growth-stock recommendation article listing three speculative names and summarizing their business model, risks, and selected financial/policy context.
Ticker impact
Joby is highlighted as an eVTOL long-term bet, with the article noting U.S. aircraft approval is still pending and could arrive this year.
Limited immediate impact; any move would likely depend on future approval-related headlines rather than this article alone.
This is primarily a long-horizon thesis recap; the only time-linked item is a possibility of approval “as early as this year,” without new data or an announced decision.
Curaleaf is discussed in the context of U.S. medical marijuana rescheduling, with the article suggesting broader reform could be on the horizon.
Moderate sensitivity to follow-on federal headlines; this article itself is unlikely to be a standalone catalyst.
It references a policy backdrop (rescheduling) and general optimism, but provides no incremental Curaleaf-specific event beyond the narrative.
Pony AI is presented as a robotaxi growth story, citing Q1 revenue growth and ongoing operating losses as key risk/reward inputs.
Potentially supportive for momentum traders, but likely capped by the continued unprofitability emphasized in the article.
Unlike the other two, the article includes concrete recent performance figures (Q1 revenue up 145% YoY; operating loss $58.3M over past three months), which are directly decision-relevant for traders.
Market effects
Highlights three high-uncertainty growth themes: eVTOL regulatory approval timelines, cannabis federal policy optionality, and robotaxi scaling vs. burn.
Pony AI’s mention of Europe’s first robotaxi service (Croatia) underscores cross-region commercialization efforts.
Robotaxi and eVTOL narratives are globally relevant to autonomy/transport investment sentiment, while cannabis remains highly policy-dependent in the U.S.
Counterpoint
The “10x returns” framing is promotional and may over-weight speculative catalysts (approval/legalization) while under-weighting dilution, financing risk, and execution delays.
Key entities
- companyJoby Aviation
eVTOL company; U.S. aircraft approval not yet granted per article, with potential timing “as early as this year.”
- companyCuraleaf Holdings
Cannabis operator; article cites operating profitability and ties upside to U.S. medical marijuana rescheduling and possible broader reform.
- companyPony AI
Robotaxi software/hardware provider; article cites Q1 revenue growth and continued operating losses.
